The British Journal of Psychiatry (2007) 190: 531-532. doi: 10.1192/bjp.bp.106.031393
© 2007 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data supplements
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by NORBURY, R.
Right arrow Articles by HARMER, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by NORBURY, R.
Right arrow Articles by HARMER, C. J.

SHORT REPORTS

Short-term antidepressant treatment and facial processing

Functional magnetic resonance imaging study

RAY NORBURY, PhD and CLARE E. MACKAY, PhD

University of Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital, Oxford

PHILIP J. COWEN, MD, FRCPsych, GUY M. GOODWIN, DPhil, FRCPsych, FMedSci and CATHERINE J. HARMER, DPhil

University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, UK

Correspondence: Correspondence: Dr Ray Norbury, University of Oxford Centre for Clinical Magnetic Resonance Research, MRS Unit, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK. Email: raymond.norbury{at}psych.oxford.ac.uk

Declaration of interest None.

We used functional magnetic resonance imaging to investigate the effects of short-term treatment with reboxetine, a selective noradrenaline reuptake inhibitor, on emotional facial processing in healthy volunteers. Reboxetine was associated with a reduced amygdala response to fearful faces and increased activation to happy v. neutral facial expressions in the right fusiform gyrus, relative to placebo treatment and in the absence of changes in mood. Our results show that reboxetine modulates the neural substrates of emotional processing, highlighting a mechanism by which drug treatment could normalise negative bias in depression and anxiety.




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
C. J. Harmer, G. M. Goodwin, and P. J. Cowen
Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action
The British Journal of Psychiatry, August 1, 2009; 195(2): 102 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Soc Cogn Affect NeurosciHome page
O. A. Onur, H. Walter, T. E. Schlaepfer, A. K. Rehme, C. Schmidt, C. Keysers, W. Maier, and R. Hurlemann
Noradrenergic enhancement of amygdala responses to fear
Soc Cogn Affect Neurosci, June 1, 2009; 4(2): 119 - 126.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
M Di Simplicio, R Massey-Chase, P. Cowen, and C. Harmer
Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers
J Psychopharmacol, May 1, 2009; 23(3): 241 - 248.
[Abstract] [PDF]

Home page
 J. Neurosci.Home page
J. Kukolja, T. E. Schlapfer, C. Keysers, D. Klingmuller, W. Maier, G. R. Fink, and R. Hurlemann
Modeling a Negative Response Bias in the Human Amygdala by Noradrenergic-Glucocorticoid Interactions
J. Neurosci., November 26, 2008; 28(48): 12868 - 12876.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
S. HAFIZI, P. CHANDRA, and J. COWEN
Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations
The British Journal of Psychiatry, October 1, 2007; 191(4): 282 - 284.
[Abstract] [Full Text] [PDF]